At the news
? NEUTRALIMPACT 2/10 144 filed Aug 10, 2026 at 16:34 ET
Simon Read, an officer of Dianthus Therapeutics, filed a Form 144 to sell 5,550 shares of common stock valued at approximately $624,375, with the sale to be executed through a 10b5-1 plan adopted on May 8, 2026. The filing is a routine advance notice of an intended sale under a pre-arranged trading plan and does not indicate a change in the insider's view of the company's prospects. Given the small size of the proposed sale relative to the company's $6.1B market cap, the filing is neutral and low-impact.
- Officer Simon Read filed a Form 144 to sell 5,550 shares of common stock.
- The estimated aggregate market value of the proposed sale is $624,375.
- The sale is to be made pursuant to a 10b5-1 selling plan dated May 8, 2026.
- The proposed sale represents a very small fraction of the company's $6.1B market capitalization.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access